Irritable bowel syndrome and gut microbiota

Area of Science:

• Gastroenterology
• Microbiology
• Psychiatry

Background:

• Irritable bowel syndrome (IBS) is associated with significant alterations in the gut microbiota, termed dysbiosis.
• Dysbiosis impacts intestinal permeability, inflammation, gut motility, and quality of life, influencing both gastrointestinal and central nervous system functions.
• IBS patients exhibit distinct gut microbiota signatures correlated with symptom severity and increased risk of depression and anxiety.

Purpose of the Study:

• To review recent research on the role of the gut microbiota in the pathogenesis of IBS.
• To explore current and emerging treatment strategies targeting gut dysbiosis in IBS.
• To provide an overview of the relationship between microbiota changes and IBS symptoms.

Main Methods:

• Systematic review of recent studies on IBS and gut microbiota.
• Analysis of findings from clinical trials and observational studies.
• Synthesis of evidence regarding the impact of dysbiosis on IBS.

Main Results:

• Gut bacterial disturbances are primary contributors to IBS development and symptom severity.
• Treatments like the low FODMAP diet, rifaximin, and fecal microbiota transplant have shown limited or transient effects on IBS symptoms and microbiota.
• Despite identified microbiota changes, current therapeutic interventions modulating gut dysbiosis offer little sustained improvement for IBS.

Conclusions:

• Gut microbiota dysbiosis is a key factor perpetuating IBS symptoms.
• Further research is needed to develop effective treatments that exploit microbiota disturbances for IBS management.
• The complex interplay between gut microbiota and IBS necessitates innovative therapeutic approaches.